

Oncología personalizada de precisión: situación actual y perspectivas de futuro

Personalized Precision Oncology: current status and future perspectives

Madrid, 21 y 22 de marzo / March 21-22, 2019

BIO

Manuel Hidalgo, M.D., Ph.D.

Director, Leon V. & Marilyn L. Rosenberg Clinical Cancer Center
Chief, Division of Hematology–Oncology
Co-Director, Pancreatic Cancer Research Program



Manuel Hidalgo, M.D., Ph.D., is director of the Leon V. & Marilyn L. Rosenberg Clinical Cancer Center, chief of the Division of Hematology–Oncology, and co-director of the Pancreatic Cancer Research Program at Beth Israel Deaconess Medical Center (BIDMC). He is also a professor of medicine at Harvard Medical School.

Dr. Hidalgo received his M.D. from the University of Navarra and his Ph.D. from the University Autonoma of Madrid. He completed a fellowship in anticancer drug development at the University of Texas Health Science Center in San Antonio. In 2001, Dr. Hidalgo joined Johns Hopkins University School of Medicine as an associate professor and in 2003, became co-director of its Gastrointestinal Cancer Program. A native of Spain, Dr. Hidalgo came to BIDMC in 2015 from the Centro Nacional de Investigaciones Oncológicas (Spanish National Cancer Center) where he served as director of the Clinical Research Program and vice director of Translational Research.

An internationally respected oncologist, Dr. Hidalgo is a world leader in the testing and development of new agents for pancreatic and other solid tumor cancers. He oversees all BIDMC clinical cancer programs.

Dr. Hidalgo is a founder of the Pancreatic Cancer Research Team (PCRT), a private nonprofit cooperative group dedicated to rapid drug development in pancreatic cancer. He is member of the Science Committee of Cancer Research UK and Special Conferences Committee of the American Association of Cancer Research. Dr. Hidalgo is scientific editor of *Cancer Discovery*.